Browse EPHA1

Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF14575 Ephrin type-A receptor 2 transmembrane domain
PF01404 Ephrin receptor ligand binding domain
PF00041 Fibronectin type III domain
PF07714 Protein tyrosine kinase
PF00536 SAM domain (Sterile alpha motif)
Function

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds with a low affinity EFNA3 and EFNA4 and with a high affinity to EFNA1 which most probably constitutes its cognate/functional ligand. Upon activation by EFNA1 induces cell attachment to the extracellular matrix inhibiting cell spreading and motility through regulation of ILK and downstream RHOA and RAC. Plays also a role in angiogenesis and regulates cell proliferation. May play a role in apoptosis.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001933 negative regulation of protein phosphorylation
GO:0001952 regulation of cell-matrix adhesion
GO:0001954 positive regulation of cell-matrix adhesion
GO:0006469 negative regulation of protein kinase activity
GO:0007015 actin filament organization
GO:0007160 cell-matrix adhesion
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019827 stem cell population maintenance
GO:0030038 contractile actin filament bundle assembly
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0031032 actomyosin structure organization
GO:0031589 cell-substrate adhesion
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033673 negative regulation of kinase activity
GO:0034446 substrate adhesion-dependent cell spreading
GO:0035019 somatic stem cell population maintenance
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0042326 negative regulation of phosphorylation
GO:0043149 stress fiber assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0046777 protein autophosphorylation
GO:0048013 ephrin receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0051017 actin filament bundle assembly
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051348 negative regulation of transferase activity
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0061572 actin filament bundle organization
GO:0090630 activation of GTPase activity
GO:0098727 maintenance of cell number
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005003 ephrin receptor activity
GO:0005005 transmembrane-ephrin receptor activity
GO:0019199 transmembrane receptor protein kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04360 Axon guidance
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EPHA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EPHA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EPHA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.510.232
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0840.903
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9580.115
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1240.776
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2060.925
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.540.844
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6820.406
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0740.367
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.150.904
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6060.0409
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8130.1
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1430.348
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EPHA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPHA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPHA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPHA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPHA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EPHA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EPHA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEPHA1
NameEPH receptor A1
Aliases EPH; EPHT; EPHT1; eph tyrosine kinase 1; erythropoietin-producing hepatoma amplified sequence; erythropoieti ......
Chromosomal Location7q32-q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EPHA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.